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Abstract
The aim of our study was to determine the epidemiological profile and the antibiotic susceptibility of bacteria and fungi identified from blood
cultures in the patients of the clinical haematology unit. A retrospective study was carried out over an 8-year period (2003–2010) in the
clinical haematology unit of the Percy Military Medical Center. During this period, we collected 723 isolates: Gram-negative bacilli (70.8%)
and Gram-positive cocci (18.7%). The four most commonly isolated species were Escherichia coli (18.5%), Pseudomonas aeruginosa (14.8%),
Stenotrophomonas maltophilia (6.2%) and Staphylococcus epidermidis (5.4%). The rate of methicillin-resistant Sthaphylococcus aureus was 6.45%
and that of coagulase-negative staphylococci 61.2%. No resistance to glycopeptides was observed. In E. coli, as in the Klebsiella-Ente-
robacter-Serratia group, a 27% resistance to fluoroquinolones was observed. Concerning P. aeruginosa, the phenotypes were distributed
over penicillinase (23.4%) and cephalosporinase (13.1% were resistant to ceftazidime). The impermeability rate of imipenem was 9.3%. The
aggressiveness and duration of haematological treatments explains why infections remain one of the main complications of neutropenia. The
emergence of new or unusual bacteria is highly likely. Antibiotic selective pressure and long periods of hospitalization could explain the
emergence of multiresistant bacteria. As a consequence, epidemiological surveillance is indispensable.
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Abstract
In 2010 a case of a dual infection with Legionella pneumophila serogroup (sg) 1 and sg 3 was identified by culture of a blood sample collected
from a female Austrian patient with septic pneumonia. Subsequently all 35 European National Legionella Reference Laboratories were
interviewed regarding the frequency of dual infections in legionellosis. The Reference Laboratories in Denmark, the UK and Germany
reported the detection of another 14 cases of dual infections with different Legionella strains between 2002 and 2012. Among the 15 cases,
there were four cases with different Legionella species, six cases with different L. pneumophila serogroups, and five cases of dual infections
with L. pneumophila sg 1 with different MAb-types. The median age of the 15 cases was 56 years and the male to female ratio 1:1.14. Six of
the 15 patients were receiving immunosuppressive treatment following organ transplantation (n = 3) or for underlying haematological and
solid malignancies (n = 3). Five of the 15 cases died within 30 days following diagnosis. Efforts to detect dual infections with different
Legionella strains will improve our ability to correctly elucidate the causative sources of infection and enhance our understanding of the
epidemiology of Legionella infections.
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Abstract
Since the end of the last century resistance to oxyimino b-lactams has steadily increased in Enterobacteriaceae. In the present work we
studied extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae strains isolated in the teaching hospital of Clermont-Ferrand,
France, between 2006 and 2009. A total of 1368 ESBL-producing isolates were collected. Most of these isolates (69%) were
CTX-M-producing Escherichia coli. During the study, the clinical incidence increased by more than 400%, even in the emergency department,
and especially in community-acquired infections, as is the case elsewhere in the world. Most of the ESBL-producing isolates remained
susceptible to furans and fosfomycin, but only 50% to fluoroquinolons. In conclusion, ESBL-producing bacteria constantly increased during
the study period. Unlike many studies, this increase was associated with the wide dissemination of three different CTX-M enzymes:
CTX-M-14, CTX-M-15 and CTX-M-1.
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